Patents

Granted Patents

  • Saarma M., Pulkkila P., Voiutilainen M., Peranen J., Tuominen R., Airavaara M., Leppanen V-M., Lindahl M., Andressoo J-O. Neurotrophic factor MANF and uses thereof. United State Patent US 9,592,270 B2, March 14, 2017
  • Saarma M., Karelson M., Bespalov M., Pilv M. Methods facilitating neuronal survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators. European Patent, No 2509953, issued 7.03.2016 and published in the European Patent Bulletin on 30.03.2016.
  • Nevalaita L., Saarma M. Splice variants of GDNF and uses thereof. European Patent, positive decision to 12 189 585.8-1456, April 20, 2015.
  • Saarma M., Karelson M., Bespalov M., Pilv M. Methods facilitating neuronal survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators. US Patent No 8,901,129, December 2, 2014.
  • Saarma M., Lindholm P., Voutilainen M., Peranen J., Tuominen R., Airavaara M., Leppanen V-M, Lindahl M., Andressoo J-O (2014). Neurotrophic factor MANF and uses thereof. US Patent 8,853,166.  October 7, 2014.
  • Penn R., Runeberg-Roos P., Bespalov M.M., Saarma M. Neurturin molecules, US Patent 8,445,432. May 21, 2013.
  • Saarma M., Karelson M., Pilv M., Bespalov M.M. Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signalling pathway activators European Patent No 10790954.1-2101, 2012.
  • Karelson M., Saarma M., Pilv M. Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease. US Patent US 7,786,292 B2. Aug.31, 2010.
  • Sariola, H., Sainio, K., Suvanto, P., Arumäe, U., Lindahl, M. & Saarma, M. Glial Cell-Line Derived Neurotrophic Factor Ureteric Budding and Growth: USA (5,882,923).
  • Saarma, M., Kelve M., Truve E., Teeri, T. Reconstitution of multiple virus resistance in transgenic plants: Austria (AU 669130), USA (5589625), EP92920421
  • Ylikoski J., Pirvola U., Saarma M., Walton K.M., and Hudkins R.L. Methods preventing/treating damage to sensory hair cells and cochlear neurons: USA (6,448,283)
  • Ibañéz C.F., Arumäe U., Sariola H., Suvanto P., Trupp M., and Saarma M. Glial cell line-derived neurotrophic factor receptors: New Zealand (501199)
  • Ibañéz C.F., Arumäe U., Sariola H., Suvanto P., Trupp M., and Saarma M. GDNFR-beta as an accessory protein for GDNF family ligands: USA (98/09056)
  • Titievsky A., Poteriaev D., Arumäe U., and Saarma M. Ret-independent signaling pathway for GDNF (3266): USA (US6905817)
  • Ibañéz C.F., Arumäe U., Sariola H., Suvanto P., Trupp M., and Saarma M. Glial cell line derived neurotrophic factor receptors (GFRalpha2) (3256): New Zealand (NZ324511, NZ336245, NZ501199), Australia (AU741208, AU718979), USA (US6696259)
  • Airaksinen M., Saarma M., Poteriaev D., Lindahl M., Timmusk T., Rossi, J. Compounds related to or derived from GFRalpha4 and their use (3230): Australia (AU782897), Europe, registered in UK, Ireland, Germany, Switzerland (EP1257581)
  • Saarma M., Laurikainen A.M., Hiltunen J-O., Airaksinen M.S., Klinge E.M. Neurotrophic factors in the treatment of nerve dysfunctions in the pelvic area (3225): Australia (AU776275), New Zealand (NZ51537), (European Patent. EP 1 181 042 B1).
  • Saarma M., Lauren J., Lindholm P., Timmusk T., Tuominen R.  Neurotrophic factor protein and uses thereof. US patent issued with the number 7,452,969 on November 18, 2008.